Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Wednesday, 14 May 2014
MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Monday, 3 February 2014
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance AstraZeneca today announced that it has completed, on 1 February 2014, its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
Tuesday, 14 January 2014
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth Pascal Soriot, Chief Executive Officer, AstraZeneca will today present at the JP Morgan Healthcare Conference in San Francisco, CA at 4:30 pm Pacific time. At the conference, Pascal Soriot will provide an update on the company’s development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar